Tuesday, January 07, 2025 11:21:54 AM
Wow!!! CERo : 1 for 100 R/S: Therapeutics Holdings, Inc. Announces Reverse Stock Split
2025-01-06 08:00 ET - News Release
SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-one hundred reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).
The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 8, 2025, and the Company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Global Market (“Nasdaq”) as of the opening of trading on January 8, 2025. The CUSIP number of 71902K303 will be assigned to the Company’s Common Stock when the reverse stock split becomes effective.
2025-01-06 08:00 ET - News Release
SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-one hundred reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).
The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 8, 2025, and the Company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Global Market (“Nasdaq”) as of the opening of trading on January 8, 2025. The CUSIP number of 71902K303 will be assigned to the Company’s Common Stock when the reverse stock split becomes effective.
Recent CERO News
- CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial • GlobeNewswire Inc. • 05/11/2026 12:15:00 PM
- CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial • GlobeNewswire Inc. • 04/14/2026 12:15:00 PM
- CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial • GlobeNewswire Inc. • 03/30/2026 12:15:00 PM
- CERo Therapeutics Provides Shareholder Update • GlobeNewswire Inc. • 03/11/2026 12:15:00 PM
- CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors • GlobeNewswire Inc. • 02/17/2026 01:00:00 PM
- CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient • GlobeNewswire Inc. • 02/04/2026 02:05:00 PM
- CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML • GlobeNewswire Inc. • 01/07/2026 02:09:00 PM
- CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) • GlobeNewswire Inc. • 12/17/2025 01:00:00 PM
- CERo Therapeutics Announces Trading on OTCQB Market • GlobeNewswire Inc. • 12/02/2025 12:30:00 PM
- CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing • GlobeNewswire Inc. • 11/05/2025 01:00:00 PM
- CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response • GlobeNewswire Inc. • 11/04/2025 02:05:00 PM
- CERo Therapeutics Announces Listing on OTC Markets • GlobeNewswire Inc. • 11/03/2025 01:00:00 PM
- CERo Therapeutics Announces Receipt of Nasdaq Panel Determination • GlobeNewswire Inc. • 10/29/2025 11:22:58 PM
- CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML • GlobeNewswire Inc. • 10/21/2025 12:15:00 PM
- CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 • GlobeNewswire Inc. • 10/15/2025 12:30:00 PM
- CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML • GlobeNewswire Inc. • 10/13/2025 12:30:00 PM
- CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort • GlobeNewswire Inc. • 09/22/2025 01:15:00 PM
- CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 • GlobeNewswire Inc. • 09/09/2025 12:15:00 PM
- CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia • GlobeNewswire Inc. • 09/08/2025 12:45:00 PM
- CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML) • GlobeNewswire Inc. • 09/05/2025 12:00:00 PM
- CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 • GlobeNewswire Inc. • 07/31/2025 12:10:00 PM
- CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 • GlobeNewswire Inc. • 06/23/2025 12:15:00 PM
- CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) • GlobeNewswire Inc. • 06/17/2025 12:15:00 PM
- CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split • GlobeNewswire Inc. • 06/11/2025 01:10:00 PM
- CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing • GlobeNewswire Inc. • 06/06/2025 12:15:00 PM
